Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung‐Jue Bang(Seoul National University), Yoon‐Koo Kang(Ulsan College), Atsushi Ohtsu(National Cancer Center Hospital East), Josef Rüschoff(University of Kassel), A. Feyereislova(Roche (Switzerland)), Akira Sawaki(Aichi Cancer Center), Florian Lordick(Leipzig University), Taroh Satoh(Osaka University Hospital), Michaela Lehle(Roche (Switzerland)), Lin Shen(Peking University), Е. С. Куликов(State Healthcare Institution "Regional Clinical Oncological Dispensary"), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Hyun Cheol Chung(Yonsei University), Yasushi Omuro(Tokyo Metropolitan Komagome Hospital), Julie Hill(Roche (Switzerland))
Cited by 7,282
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k